The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia | Zendy

Terry Golombick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia

Author(s) -

Terry Golombick

Publication year - 2008

Publication title -

biologics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.948

H-Index - 38

eISSN - 1177-5491

pISSN - 1177-5475

DOI - 10.2147/btt.s2514

Subject(s) - paraproteinemia , dyscrasia , multiple myeloma , plasma cell , monoclonal gammopathy of undetermined significance , curcumin , medicine , gammopathy , paraproteinemias , immunology , cancer research , pharmacology , monoclonal , monoclonal antibody , antibody

Plasma cell dyscrasias, most commonly associated with paraproteinemia, are a diverse group of diseases. Monoclonal gammopathy of undefined significance (MGUS) can precede multiple myeloma, a progressive neoplastic disease. MGUS occurs in association with a variety of other diseases and currently no treatment is recommended but rather "watchful waiting". Given that the size of the M-protein is a risk factor for disease progression, early intervention with the aim of reducing the paraprotein load would provide an innovative therapeutic tool. Preliminary results from our pilot study show a drop of between 5% and 30% serum paraprotein in patients taking curcumin compared with patients on placebo. Curcumin is a diferuloylmethane present in extracts of the rhizome of the Curcuma longa plant. As a natural product, this has exciting potential in the treatment of plasma cell dyscrasias.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research